In orthotropic KRAS-driven EZH positive NSCLC grafts, treatment with EZH2 inhibitor GSK126 could amplify inflammation through activation of NF-ĸB and genes residing within the PRC-2 regulated chromatin. This evidence concerns the gene KRAS and non-small cell lung carcinoma.